Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study

Dermatol Surg. 2002 Sep;28(9):822-7. doi: 10.1046/j.1524-4725.2002.02039.x.

Abstract

Background: Recent studies demonstrate that botulinum toxin type A (BTX-A) decreases palmar hyperhidrosis.

Objective: To evaluate the efficacy and safety of BTX-A for palmar hyperhidrosis.

Methods: Patients (n = 19) received injections of placebo (normal saline) in one hand and BTX-A in the other. Assessments included gravimetric measurement of sweat production and physician's and patient's rating of severity. Safety evaluations included measuring grip strength. Preliminary 28-day results are reported.

Results: The mean percentage decrease in gravimetric measurement at day 28 was significantly greater with BTX-A versus placebo. One hundred percent of 17 patients rated the treatment as successful, while only 12% (2/17) rated placebo injection successful. Grip and hand strength were unchanged with either treatment. Only 21% (4/19) reported mild adverse events.

Conclusion: BTX-A injections produce significant improvements in palmar hyperhidrosis without a concomitant decrease in grip or dexterity, or the occurrence of serious adverse events.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Botulinum Toxins, Type A / therapeutic use*
  • Double-Blind Method
  • Hand
  • Hand Strength
  • Humans
  • Hyperhidrosis / drug therapy*
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A